Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 plus apatinib in EGFR-mutant advanced NSCLC after EGFR-TKI failure
ChiCTR1900028363Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Union Hospital. Primary endpoint: Progression-free survival. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900028363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028363.